The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir.
Burger
David M
DM
Schwietert
H Reinier
HR
Colbers
E P H
EP
Becker
Mark
M
D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065731:Cytochrome P-450 CYP2C19; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics*; D006579:Heterozygote; D006801:Humans; D006899:Mixed Function Oxygenases / Q000235:genetics*; D009154:Mutation; D019888:Nelfinavir / Q000493:pharmacokinetics*; D011110:Polymorphism, Genetic
D017320:HIV Protease Inhibitors; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D019888:Nelfinavir